08.26.2022
After pivotal clinical trials, PENTAS (President: Tomohiko Kanai; Headquarters: Shibuya, Tokyo) received PMDA approval for its ‘PENTAS Treatment Planning Program’ and its ‘PENTAS stent’ for domestic commercialization on August 26, 2022. PENTAS has been researching a practical solution that integrates ‘Computational Fluid Dynamics’ (CFD) to optimize the analysis of cerebrovascular fluids. While CFD is being utilized for the treatment of cerebral aneurysm, it has not permeated into a clinical setting due to several limitations. However in recent years, PENTAS successfully developed the world’s first CFD software which calculates the cerebrovascular fluids and simulates the effects of stents on diseases, offering a practical solution to the use of CFD for cerebral aneurysm treatment.
After being established as a subsidiary of Allm in 2015, Pentas began manufacturing and developing the ‘PENTAS treatment planning program’ and ‘PENTAS stent’ shortly thereafter. Allm is in charge of the development of this program, along with support from several institutions including the Japan Agency for Medical Research And Development (AMED) and Professor Yuichi Murayama from the Jikei University School of Medicine, Department of Neurosurgery.
PENTAS is pioneering the field of Neuroendovascular treatment with its novel approach to cerebral aneurysm treatment. Fast Track Initiative has been supporting PENTAS since 2018 as the company continues to strive to enable safer, more practical stent treatment in the future.
About PENTAS:
PENTAS is a medical device/software company based out of Tokyo, Japan, working to innovate cerebral aneurysm treatment since 2015. The company has been researching a visualization technique that integrates IT and medical devices to optimize the treatment of cerebral aneurysm. PENTAS developed the world’s first ‘Computational Fluid Dynamics’ (CFD) software which calculates cerebrovascular fluids and simulates the effects of stents on diseases. Through its national research and development granted projects, the company also manufactures and sells virtual/intracranial stents and microcatheters. Visit us at https://pentas.allm.net for more details.
About Fast Track Initiative:
Established in 2004, Fast Track Initiative, Inc. (FTI) is a life science venture capital firm focusing its investments on grow seed and early-stage startups with a strong focus on biotech and therapeutics. FTI has a strict mission to make a ground-breaking impact on the quality of our life and human wellness through investments across a broad range of areas in the life science community including diagnostics, digital health, healthcare services, and more. The company provides full, hands-on operational support to its 30+ portfolio companies through business and R&D strategy, investor syndication, and more, including access to its exclusive network of leading industry professionals in Japan. Visit https://us.fasttrackinitiative.com for more details, or follow us on LinkedIn: https://www.linkedin.com/company/fast-track-initiative/. For press inquiries or investor inquiries, please email: message.us@fasttrackinitiative.com
